Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Disease Progression 1Breast Neoplasms 1

Interventions

tumor necrosis factor-alpha, CNGRC fusion protein, human 2liposomal doxorubicin 2Doxorubicin 2niraparib 1copanlisib 1Standard of Care 1Saline Solution 1Practice Guidelines as Topic 1Palliative Care 1Paclitaxel 1Lidocaine 1Gemcitabine 1Conservative Treatment 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease Progression × Clinical Trials, Phase II as Topic × Gynecologic × Clear all
NCT04503265 2025-05-01

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

AtlasMedx, Incorporated

Phase 1/2 Recruiting
122 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡